Back to discover
Disease

Latent Tuberculosis

Late-stage therapeutic developmentEmerging research
MeSHLatent Tuberculosis
4
Publications
17
Clinical trials
2
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q1 2027.
  • 1 industry development reported.
Upcoming Milestones
Clinical Milestones5View
Results expected 2
Recently completed 3
Industry & Market1View
Activity timeline6

Clinical trials

14 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
17
All trials
6
Active
14
Late-stage
6
Completed
Late-stage studies

Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness

Phase 2/3 · Recruiting · Centers for Disease Control and Prevention

One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

Phase 4 · Active, not recruiting · Rutgers, The State University of New Jersey

Phase IV Clinical Trial of the Safety, Efficacy, and Immunogenicity of Mycobacterium Vaccae for Injection (Mica) in People Over 15 Years of Age With Latent Mycobacterium Tuberculosis Infection

Phase 4 · Active, not recruiting · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)

Phase 3 · Recruiting · Huashan Hospital

Directly Observed Preventive Therapy (DOPT) for Latent Tuberculosis Infection Patients With Poorly Controlled Diabetes Mellitus

Phase 4 · Active, not recruiting · Taichung Veterans General Hospital

A Multicenter, Randomized, Double-blind, Controlled Phase Ⅲ Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) for the Diagnosis of Mycobacterium Tuberculosis Infection in 65-year-olds and Above

Phase 3 · Completed · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Recently completed

A Multicenter, Randomized, Double-blind, Controlled Phase Ⅲ Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) for the Diagnosis of Mycobacterium Tuberculosis Infection in 65-year-olds and Above

Phase 3 · Completed · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

To Conduct a Phase IV Clinical Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein in Community Population Aged 6 Months and Above.

Phase 4 · Completed · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Comparing Incidence Rate of Systemic Drug Reactions Under 3HP and 1HP Regimen for Latent Tuberculosis Infection Treatment: a Pragmatic Multicenter Randomized Control Trial

Phase 3 · Completed · National Taiwan University Hospital

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

Phase 4 · Completed · Herlev and Gentofte Hospital

Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren

Phase 3 · Completed · Queen Mary University of London

A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness

Phase 3 · Completed · McGill University

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2017–2023
Major themes7
  • Latent Tuberculosis3
  • Mycobacterium tuberculosis2
  • Tuberculosis2
  • Communicable Diseases1
  • COVID-191
  • Interleukin-271
  • Tuberculosis, Pulmonary1
Leading journals4
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
  • Frontiers in immunology1
  • Military Medical Research1
  • Scientific reports1
Leading researchers8
  • Aiello A1
  • Cohn DL1
  • Daley CL1
  • Desmond E1
  • Eugenin E1
  • Goletti D1
  • Gong WP1
  • Kazmi SU1
Affiliations (unnormalised)6
  • Aga Khan University Hospital1
  • Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment1
  • Centers for Disease Control and Prevention1
  • Dadabhoy Institute of Higher Education1
  • Dow University of Health Sciences1
  • Emory University School of Medicine and.1

Related conditions

2 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Tuberculosis3Tuberculosis, Pulmonary2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.

Identifiers
MeSHLatent Tuberculosis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.